Clinical trials: Advanced/Metastatic Neuroendocrine Tumors
Melanoma
Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy
The purpose of this study is to describe the safety and effectiveness of nivolumab treatment, either in monotherapy or in combination with ipilimumab, overall and according to various subgroups of interest, in participants with…
- Trial name
- NICO (NCT02990611)
- Where
- Germany
- Volunteers
- 1,087 people
- Sponsor
- Bristol-Myers Squibb
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
Gastroenteropancreatic Neuroendocrine Tumors
Community-based Neuroendocrine Tumor (NET) Research Study
The purpose of this trial is to assess time to disease progression of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with Lanreotide Depot.
- Trial name
- NCT02730104
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ipsen
Uveal Melanoma, Ocular Melanoma
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma.
- Trial name
- OCULE-01 (NCT06717126)
- Testing
- roginolisib, Investigator choice of standard therapy
- Where
- 16 sites in Italy, Spain and 1 more
- Volunteers
- 85 people
- Sponsor
- iOnctura
Metastatic Melanoma
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
The primary purpose of this study is to demonstrate that the NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab is safe for the treatment of patients with advanced or metastatic melanoma.
- Trial name
- NCT03597282
- Testing
- NEO-PV-01, Nivolumab, Adjuvant
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- BioNTech US Inc.
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Metastatic Melanoma and Other Solid Tumors
A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer
Researchers are looking for a better way to treat people who have advanced cancer. In this study researchers want to learn more about a new substance called BAY2666605.
- Trial name
- NCT04809805
- Testing
- BAY2666605
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Bayer
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Breast Neoplasms, Prostate Neoplasms
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.
- Conditions
- Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma
- Trial name
- NCT03685591
- Testing
- PF-06952229, Enzalutamide
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Pfizer
Pancreatic Cancer, Breast Cancer
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05311618
- Testing
- NGM438, Pembrolizumab (KEYTRUDA ®)
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Melanoma Stage IV, Melanoma Stage III
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
BERING-MELANOMA - designed as a prospective, longitudinal, non-interventional study - investigates real-world effectiveness, quality of life, safety and tolerability of encorafenib plus binimetinib in unresectable advanced or…
- Trial name
- BERING (NCT04045691)
- Testing
- Encorafenib, Binimetinib
- Where
- 59 sites in Austria, Germany and 1 more
- Volunteers
- 750 people
- Sponsor
- Pierre Fabre Pharma GmbH
Neoplasms, Melanoma
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
This study has 2 phases. The main aims of Phase 1b are: to check for side effects from modakafusp alfa in adults with locally advanced or metastatic solid tumors.
- Trial name
- NCT04157517
- Testing
- Modakafusp Alfa, Pembrolizumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 45 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 36 sites in United States, Australia and 8 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Kidney Cancer, Melanoma (Skin)
Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer
RATIONALE: Interleukin-7 may stimulate the white blood cells to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with metastatic melanoma or locally…
- Trial name
- NCT00492440
- Testing
- recombinant interleukin-7, gene expression analysis, polymerase chain reaction
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Cytheris SA
Melanoma
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
A Phase 2 study investigating the efficacy and safety of ONCOS-102 alone or in combination with balstilimab (a programmed death receptor-1 [PD-1] inhibitor).
- Trial name
- NCT05561491
- Testing
- ONCOS-102, Balstilimab
- Sponsor
- Targovax Oy
Cancer, Solid Tumor
Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
The present study has 5 parts. In Parts A and A1, the dose of intravenous (IV) pembrolizumab (MK-3475) will be escalated from 1 to 10 mg/kg to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for…
- Trial name
- KEYNOTE-001 (NCT01295827)
- Testing
- Pembrolizumab
- Volunteers
- 1,260 people
- Sponsor
- Merck Sharp & Dohme LLC
Urothelial Carcinoma, Renal Cell Carcinoma
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
The objective of this study is to assess the overall response rate, evaluate the antitumor activity, and characterize the safety and tolerability of BGB-A445 alone or in combination with tislelizumab in participants With Advanced…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma
- Trial name
- NCT05661955
- Testing
- BGB-A445, Tislelizumab
- Where
- 18 sites in China
- Volunteers
- 113 people
- Sponsor
- BeiGene
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA